Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 712

1.

Ion channels on microglia: therapeutic targets for neuroprotection.

Skaper SD.

CNS Neurol Disord Drug Targets. 2011 Feb;10(1):44-56. Review.

PMID:
21143139
2.
3.

Involvement of the intracellular ion channel CLIC1 in microglia-mediated beta-amyloid-induced neurotoxicity.

Novarino G, Fabrizi C, Tonini R, Denti MA, Malchiodi-Albedi F, Lauro GM, Sacchetti B, Paradisi S, Ferroni A, Curmi PM, Breit SN, Mazzanti M.

J Neurosci. 2004 Jun 9;24(23):5322-30.

4.

Neuronal injury in chronic CNS inflammation.

Zindler E, Zipp F.

Best Pract Res Clin Anaesthesiol. 2010 Dec;24(4):551-62. doi: 10.1016/j.bpa.2010.11.001. Epub 2010 Nov 29. Review.

PMID:
21619866
5.

The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection.

Tran TA, McCoy MK, Sporn MB, Tansey MG.

J Neuroinflammation. 2008 May 12;5:14. doi: 10.1186/1742-2094-5-14.

6.

Microglial SK3 and SK4 currents and activation state are modulated by the neuroprotective drug, riluzole.

Liu BS, Ferreira R, Lively S, Schlichter LC.

J Neuroimmune Pharmacol. 2013 Mar;8(1):227-37. doi: 10.1007/s11481-012-9365-0. Epub 2012 Apr 19.

PMID:
22527636
7.

The brain as a target for inflammatory processes and neuroprotective strategies.

Skaper SD.

Ann N Y Acad Sci. 2007 Dec;1122:23-34. Review.

PMID:
18077562
8.

Intracellular ion channel CLIC1: involvement in microglia-mediated β-amyloid peptide(1-42) neurotoxicity.

Skaper SD, Facci L, Giusti P.

Neurochem Res. 2013 Sep;38(9):1801-8. doi: 10.1007/s11064-013-1084-2. Epub 2013 Jun 7.

PMID:
23743620
9.

Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation.

Liu Y, Qin L, Li G, Zhang W, An L, Liu B, Hong JS.

J Pharmacol Exp Ther. 2003 Apr;305(1):212-8.

10.

Amyloid-β-induced reactive oxygen species production and priming are differentially regulated by ion channels in microglia.

Schilling T, Eder C.

J Cell Physiol. 2011 Dec;226(12):3295-302. doi: 10.1002/jcp.22675.

PMID:
21321937
11.

Microglial activation and its implications in the brain diseases.

Dheen ST, Kaur C, Ling EA.

Curr Med Chem. 2007;14(11):1189-97. Review.

PMID:
17504139
12.

P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases.

Takenouchi T, Sekiyama K, Sekigawa A, Fujita M, Waragai M, Sugama S, Iwamaru Y, Kitani H, Hashimoto M.

Arch Immunol Ther Exp (Warsz). 2010 Apr;58(2):91-6. doi: 10.1007/s00005-010-0069-y. Epub 2010 Feb 9. Review.

PMID:
20143170
13.

New therapeutic strategy for Parkinson's and Alzheimer's disease.

Esposito E, Cuzzocrea S.

Curr Med Chem. 2010;17(25):2764-74. Review.

PMID:
20586718
14.

Inhibition of the Ca²⁺-dependent K⁺ channel, KCNN4/KCa3.1, improves tissue protection and locomotor recovery after spinal cord injury.

Bouhy D, Ghasemlou N, Lively S, Redensek A, Rathore KI, Schlichter LC, David S.

J Neurosci. 2011 Nov 9;31(45):16298-308. doi: 10.1523/JNEUROSCI.0047-11.2011.

15.

MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease.

Culbert AA, Skaper SD, Howlett DR, Evans NA, Facci L, Soden PE, Seymour ZM, Guillot F, Gaestel M, Richardson JC.

J Biol Chem. 2006 Aug 18;281(33):23658-67. Epub 2006 Jun 14.

16.

Microglia and neuroprotection: from in vitro studies to therapeutic applications.

Polazzi E, Monti B.

Prog Neurobiol. 2010 Nov;92(3):293-315. doi: 10.1016/j.pneurobio.2010.06.009. Epub 2010 Jul 4. Review.

PMID:
20609379
17.

Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications.

Wilms H, Zecca L, Rosenstiel P, Sievers J, Deuschl G, Lucius R.

Curr Pharm Des. 2007;13(18):1925-8. Review.

PMID:
17584117
18.

3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity.

Zhang W, Qin L, Wang T, Wei SJ, Gao HM, Liu J, Wilson B, Liu B, Zhang W, Kim HC, Hong JS.

FASEB J. 2005 Mar;19(3):395-7. Epub 2004 Dec 13.

PMID:
15596482
19.

ATP-dependent potassium channel blockade strengthens microglial neuroprotection after hypoxia-ischemia in rats.

Ortega FJ, Gimeno-Bayon J, Espinosa-Parrilla JF, Carrasco JL, Batlle M, Pugliese M, Mahy N, Rodríguez MJ.

Exp Neurol. 2012 May;235(1):282-96. doi: 10.1016/j.expneurol.2012.02.010. Epub 2012 Feb 24.

PMID:
22387180
20.

Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer's disease.

Harkany T, Hortobágyi T, Sasvári M, Kónya C, Penke B, Luiten PG, Nyakas C.

Prog Neuropsychopharmacol Biol Psychiatry. 1999 Aug;23(6):963-1008. Review.

PMID:
10621945

Supplemental Content

Support Center